Samiran Panda
A5073417167- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- HIV/AIDS Research and Interventions
- HIV, Drug Use, Sexual Risk
- COVID-19 epidemiological studies
- Vaccine Coverage and Hesitancy
- SARS-CoV-2 detection and testing
- Viral gastroenteritis research and epidemiology
- Hepatitis C virus research
- HIV Research and Treatment
- Animal Virus Infections Studies
- COVID-19 and Mental Health
- COVID-19 Pandemic Impacts
- Sex work and related issues
- COVID-19 and healthcare impacts
- Long-Term Effects of COVID-19
- Hepatitis B Virus Studies
- Tuberculosis Research and Epidemiology
- Influenza Virus Research Studies
- Antifungal resistance and susceptibility
- HIV-related health complications and treatments
- Child Nutrition and Water Access
- Climate Change and Health Impacts
- vaccines and immunoinformatics approaches
- HIV/AIDS drug development and treatment
Indian Council of Medical Research
2014-2025
National Institute of Science and Technology
2025
Université de Montpellier
2024-2025
Assistance Publique – Hôpitaux de Paris
2024-2025
Institut de Recherche pour le Développement
2025
Sorbonne Université
2024-2025
Centre d'Immunologie et des Maladies Infectieuses
2024-2025
Inserm
2024-2025
National AIDS Research Institute
2019-2024
University of Cape Town
2024
As the global severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic expands, genomic epidemiology and whole genome sequencing are being used to investigate its transmission evolution. Against backdrop of emergence "variants concern" (VOCs) during December 2020 an upsurge in a state western part India since January 2021, analysis spike protein mutations using sequence structural approaches were undertaken identify possible new variants gauge fitness current circulating...
SummaryBackgroundBBV152 is a whole-virion inactivated SARS-CoV-2 vaccine (3 μg or 6 μg) formulated with toll-like receptor 7/8 agonist molecule (IMDG) adsorbed to alum (Algel). We previously reported findings from double-blind, multicentre, randomised, controlled phase 1 trial on the safety and immunogenicity of three different formulations BBV152 Algel-IMDG, Algel) one Algel-only control (no antigen), first dose administered day 0 second 14. The 3 Algel-IMDG were selected for this 2 study....
Abstract As the global severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic expands, genomic epidemiology and whole genome sequencing are being constantly used to investigate its transmissions evolution. In backdrop of emergence “variants concern” (VOCs) during December 2020 an upsurge in a state western part India since January 2021, analysis spike protein mutations using sequence structural approaches was undertaken identify possible new variants gauge fitness current...
Background & objectives: Population-based seroepidemiological studies measure the extent of SARS-CoV-2 infection in a country. We report findings first round national serosurvey, conducted to estimate seroprevalence among adult population India. Methods: From May 11 June 4, 2020, randomly sampled, community-based survey was 700 villages/wards, selected from 70 districts 21 States India, categorized into four strata based on incidence reported COVID-19 cases. Four hundred adults per...
Background & objectives: Healthcare workers (HCWs) are at an elevated risk of contracting COVID-19. While intense occupational exposure associated with aerosol-generating procedures underlines the necessity using personal protective equipment (PPE) by HCWs, high-transmission efficiency causative agent [severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)] could also lead to infections beyond such settings. Hydroxychloroquine (HCQ), a repurposed antimalarial drug, was empirically...
BackgroundThe first national severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serosurvey in India, done May–June, 2020, among adults aged 18 years or older from 21 states, found a SARS-CoV-2 IgG antibody seroprevalence of 0·73% (95% CI 0·34–1·13). We aimed to assess the more recent nationwide general population India.MethodsWe did second household individuals 10 same 700 villages wards within 70 districts India that were included serosurvey. Individuals younger than and...
Critically ill coronavirus disease 2019 (COVID-19) patients need hospitalization which increases their risk of acquiring secondary bacterial and fungal infections. The practice empiric antimicrobial prescription, due to limited diagnostic capabilities many hospitals, has the potential escalate an already worrisome resistance (AMR) situation in India. This study reports prevalence profiles infections (SIs) clinical outcomes hospitalized COVID-19 India.A retrospective admitted intensive care...
Abstract The drastic rise in the number of cases Maharashtra, India has created a matter concern for public health experts. Twelve isolates VUI lineage B.1.617 were propagated VeroCCL81 cells and characterized. Convalescent sera COVID-19 recipients BBV152 (Covaxin) able to neutralize B.1.617.
BackgroundEarlier serosurveys in India revealed seroprevalence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) 0.73% May–June 2020 and 7.1% August–September 2020. A third serosurvey was conducted between December January 2021 to estimate the SARS-CoV-2 infection among general population healthcare workers (HCWs) India.MethodsThe same 70 districts as first second serosurveys. For each district, at least 400 individuals aged ≥10 years from 100 HCWs subdistrict-level health...
SARS-CoV-2 variant of concern mainly Delta and Beta is global public health due to its impact on existing vaccines. Here, we assessed the neutralization sera from COVID-19 recovered cases BBV152 vaccinees against variants. vaccine found confer significant protection both
<h2>Summary</h2><h3>Background</h3> A systematic understanding of the burden neurological disorders at subnational level is not readily available for India. We present a comprehensive analysis disease and trends state in <h3>Methods</h3> Using all accessible data from multiple sources, we estimated prevalence or incidence disability-adjusted life-years (DALYs) 1990 to 2019 states India as part Global Burden Diseases, Injuries, Risk Factors Study 2019. assessed contribution each disorder...
ABSTRACT Background and Aims In the past decade, unmanned aerial systems (UASs), commonly known as drones, have found applications not only in military agriculture but also transportation of medical supplies. Purpose The present study was conducted to assess practicality utilizing drones a mode for delivery vaccines combat challenges. Study Design An exploratory study. Methodology Due COVID‐19 pandemic restrictions paucity availability rules regulations related India 2021, this which number...
For decades, poor treatment options and low-quality evidence plagued care for patients with rifampin-resistant tuberculosis. The advent of new drugs to treat tuberculosis enhanced funding now permit randomized, controlled trials shortened-duration, all-oral treatments We conducted a phase 3, multinational, open-label, noninferiority trial compare standard therapy fluoroquinolone-susceptible, five 9-month oral regimens that included various combinations bedaquiline (B), delamanid (D),...
Abstract The COVID-19 pandemic is a global health crisis that poses great challenge to the public system of affected countries. Safe and effective vaccines are needed overcome this crisis. Here, we develop assess protective efficacy immunogenicity an inactivated SARS-CoV-2 vaccine in rhesus macaques. Twenty macaques were divided into four groups five animals each. One group was administered placebo, while three immunized with different candidates BBV152 at 0 14 days. All challenged fourteen...
The availability of a safe and effective vaccine would be the eventual measure to deal with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) threat. Here, we have assessed immunogenicity protective efficacy inactivated SARS-CoV-2 candidates BBV152A, BBV152B, BBV152C in Syrian hamsters. Three dose vaccination regimes induced significant titers SARS-CoV-2-specific IgG neutralizing antibodies. BBV152A BBV152B remarkably generated quick robust immune response. Post-SARS-CoV-2...
ABSTRACT Background We report the clinical efficacy against COVID-19 infection of BBV152, a whole-virion inactivated SARS-CoV-2 vaccine formulated with Toll-like receptor 7/8 agonist molecule adsorbed to alum (Algel-IMDG). Methods did double-blind, randomised, multicentre, phase 3 trial in 25 Indian hospitals evaluate efficacy, safety, and immunological lot consistency BBV152. Healthy adults (age 18–98 years) randomised 1:1 using computer-generated randomisation scheme received two...
Background & objectives: India witnessed a massive second surge of COVID-19 cases since March 2021 after period decline from September 2020. Data collected under the National Clinical Registry for (NCRC) were analysed to describe differences in demographic and clinical features patients recruited during these two successive waves. Methods: The NCRC, launched 2020, is an ongoing multicentre observational initiative, which provided platform current investigation. Demographic, clinical,...
ABSTRACT Background The recent emergence of new SARS-CoV-2 lineage B.1.617 in India has been associated with a surge the number daily infections. This variant combination specific mutations L452R, E484Q and P681R reported to possibly enhance transmissibility likelihood escaping immunity. We investigated viral load pathogenic potential B.1.617.1 Syrian golden hamsters. Methods Two groups hamsters (9 each) were inoculated intranasally SARS CoV-2 isolates, B.1 (D614G) respectively. animals...
Abstract We performed the plaque reduction neutralization test (PRNT 50 ) using sera collected from recipients of BBV152/COVAXIN™ against hCoV-19/India/20203522 (UK-variant) and hCoV27 19/India/2020Q111 (heterologous strain). A comparable activity vaccinated individuals showed UK-variant heterologous strain with similar efficiency, dispel uncertainty possible escape.